Targeting Inflammation in Osteoarthritis Pain: A Phenotype-Driven Approach

Воздействие на воспаление при боли, обусловленной остеоартритом: фенотип-ориентированный подход
Wei Zheng, Chuan Huang, Shen Liu, Kai Fu
2026-10-01

imaging-defined synovitisinflammatory biomarkersinflammatory phenotypemethotrexateosteoarthritis pain
Background: Osteoarthritis (OA) is a chronic joint disease marked by the progressive loss of articular cartilage and associated inflammatory processes, which can lead to significant pain and disability. However, the heterogeneous nature of OA has limited the effectiveness of many anti-inflammatory interventions, highlighting the need for phenotype-driven therapeutic strategies. Methods: This narrative review was conducted by searching PubMed, Web of Science, and Google Scholar from inception to June 2025. Predefined keywords included "osteoarthritis", "inflammation", "pain", "synovitis", "effusion", "treatment", "therapy" and "clinical trials". Additional relevant publications were identified through citation tracking of the included papers. Results: Our analysis of recent randomized clinical trials (RCTs) reveals a clear divergence in therapeutic efficacy, while targeted biologics (eg, TNF-α inhibitors like adalimumab and IL-1 blockers such as lutikizumab) have largely failed to meet primary pain endpoints in unselected populations, broad-spectrum immunomodulators like methotrexate (MTX) show significant promise, particularly in reducing pain and stiffness for the inflammatory phenotype. Furthermore, emerging evidence suggests that intra-articular (IA) treatments and phenotype-driven stratifications are essential to overcoming the current "one-size-fits-all" failure in OA drug development. Conclusion: The central message of this review is that the inconsistent efficacy of anti-inflammatory therapies in OA reflects a patient-selection problem more than a failed target: agents tested in unselected populations, including most anti-cytokine biologics, have not relieved pain, whereas signals emerge for MTX in patients with an inflammatory phenotype. Stratifying patients by imaging-defined synovitis or effusion and inflammatory biomarkers is therefore the key unmet need, and phenotype-driven trial design-rather than new molecular targets alone-offers the most promising path to effective inflammation-targeted treatment of OA pain.
1
Intra-articular treatments and stratification using imaging-defined synovitis, effusion, and inflammatory biomarkers may improve therapeutic success.
2
Methotrexate shows promise for reducing pain and stiffness, particularly among patients with an inflammatory osteoarthritis phenotype.
3
Osteoarthritis heterogeneity likely explains inconsistent anti-inflammatory treatment efficacy and necessitates phenotype-driven therapeutic strategies.
4
TNF-α inhibition with adalimumab and IL-1 blockade with lutikizumab largely failed to meet primary pain endpoints in unselected osteoarthritis populations.
5
The review argues that patient selection and phenotype-driven trial design, rather than only identifying new molecular targets, are central unmet needs in osteoarthritis drug development.

osteoarthritis, particularly patients with inflammatory phenotypes characterized by synovitis or effusion

the phenotype-dependent efficacy of anti-inflammatory therapies in relieving osteoarthritis pain and stiffness, including the role of patient stratification by synovitis, effusion, and inflammatory biomarkers

Publication Details
Publication Date
2026-10-01
Journal
Publisher
ISSN
Cited by
1
Access Type
Author Information
Authors
Wei Zheng
Chuan Huang
Shen Liu
Kai Fu
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%